Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company pioneering novel antibiotics for resistant Gram-positive infections. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's scientific advancements and regulatory progress.
Access timely reports on clinical trial developments, including Phase 3 preparations for ibezapolstat targeting C. difficile infections. Stay informed about patent grants, research collaborations, and financial disclosures that demonstrate ACXP's commitment to addressing antimicrobial resistance through targeted DNA polymerase IIIC inhibition technology.
Our curated collection features press releases detailing milestone achievements, peer-reviewed study publications, and strategic partnership announcements. All content is verified for accuracy and relevance to support informed decision-making in the evolving antibiotic development landscape.
Bookmark this page for direct access to Acurx's latest progress in creating narrow-spectrum therapies that combat priority pathogens while preserving microbiome balance – a critical differentiator in modern infectious disease treatment.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced that its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. The company views this as a strategic move for cash not needed in the next 12-18 months, citing Bitcoin's growing demand, acceptance as a major asset class, and inflation-resistant characteristics. The company emphasized that this financial strategy will not affect their core drug development plans.
Acurx Pharmaceuticals (NASDAQ: ACXP) participated in the Peggy Lillis Foundation's Inaugural CDI Scientific Symposium, presenting updated Phase 2b clinical data for ibezapolstat. The company is preparing to advance its lead antibiotic candidate into international Phase 3 clinical trials for C. difficile Infection (CDI) treatment. Dr. Kevin Garey presented microbiome results showing ibezapolstat promotes beneficial bacteria growth while avoiding harmful Proteobacteria overgrowth. The FDA has agreed on key elements for two Phase 3 pivotal trials, requiring approximately 450 subjects in the Modified Intent-To-Treat population, randomized 1:1 between ibezapolstat and vancomycin.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported Q3 2024 financial results and business updates. The company ended Q3 with $5.8 million in cash, down from $7.5 million in December 2023. Q3 net loss was $2.8 million ($0.17 per share), compared to $3.1 million ($0.24 per share) in Q3 2023. Key developments include FDA submission for CMC meeting to commence Phase 3 trials, new patent grant for ibezapolstat extending to 2042, and positive Phase 2 trial results presentation showing comparable efficacy to vancomycin. The company raised $1.6 million through ATM financing during the quarter.
Acurx Pharmaceuticals (NASDAQ: ACXP) presented new bile acid and microbiome analyses from their Phase 2b trial of ibezapolstat for C. difficile Infection (CDI) at the IDWeek 2024 Conference. The data showed a favorable gut bile acid profile and restoration of beneficial bacteria in ibezapolstat-treated patients, which may contribute to its anti-recurrence effect. Ibezapolstat demonstrated comparable clinical cure rates and safety to vancomycin, with no recurrence in the 5 patients followed for 3 months post-treatment.
Acurx is preparing to advance ibezapolstat into international Phase 3 clinical trials for CDI treatment, following a successful FDA End-of-Phase 2 Meeting. The company plans to submit requests for regulatory guidance in the EU, UK, Japan, and Canada. Ibezapolstat has previously received FDA QIDP and Fast-Track Designation.
Acurx Pharmaceuticals (NASDAQ: ACXP), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, has announced its participation in the Spartan Capital inaugural investor conference on November 4, 2024, at the Pierre Hotel in New York. The company's CEO, David P. Luci, expressed enthusiasm about the opportunity to showcase Acurx's accomplishments and future plans to key influencers in the capital markets.
The conference, organized in partnership with B2i Digital, will feature presentations from over 30 selected companies, along with panel discussions, one-on-one meetings, and networking sessions. This event aligns with Acurx's commitment to engage with industry leaders and investors, providing a platform to offer insights into the company's growth strategy and market position.
Acurx Pharmaceuticals (NASDAQ: ACXP), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, has announced that it will discuss its third quarter 2024 financial results on Wednesday, November 13, 2024, at 8:00 am ET before the U.S. financial markets open. The company's President and CEO, David P. Luci, along with CFO Robert G. Shawah, will host a conference call to discuss the results and provide a business update.
Interested parties can join the call using the following details:
- Toll-free (U.S.): 877-790-1503
- International: Participant international Toll-Free access numbers available via provided link
- Conference ID: 13749688
New to The Street, a leading U.S. business television platform, has renewed its media partnership with Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a late-stage biopharmaceutical company. The new series includes broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign.
Acurx Pharmaceuticals will be featured on New to The Street's national television broadcasts, highlighting the company's latest developments and leadership in addressing critical bacterial infections through innovative antibiotics. The coverage will air across major networks, enhancing Acurx's visibility in the biopharmaceutical sector.
The partnership also includes targeted earned media placements and outdoor advertising support, featuring billboard placements in strategic locations like Times Square and the Financial District. The media series is set to begin airing immediately in 2024, with outdoor and earned media elements running concurrently to maximize audience reach.
New to The Street announces its upcoming sponsored programming on Bloomberg TV, airing Saturday, October 12, at 6:30 PM EST. The lineup features innovative companies including ZAPP, NUBURU, and ACURX Pharmaceuticals, showcasing advancements in electric vehicles, blue laser technology, and antibiotic innovation respectively. The program will also include The Sustainable Green Team highlighting eco-friendly solutions for environmental sustainability, and SEKUR returning with its "Hack of the Week" segment, focusing on cybersecurity threats and privacy protection.
New to The Street announces its upcoming sponsored programming on Bloomberg TV, airing Saturday, October 11, at 6:30 PM EST. The lineup features innovative companies including:
- ZAPP: Electric vehicles
- NUBURU: Blue laser technology
- ACURX Pharmaceuticals (ACXP): Antibiotic innovation
- The Sustainable Green Team: Eco-friendly solutions for environmental sustainability
- SEKUR: 'Hack of the Week' segment on cybersecurity threats and privacy protection
This diverse lineup showcases cutting-edge advancements across various industries, from electric vehicles to healthcare and environmental sustainability.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced new analyses extending data on ibezapolstat's beneficial effects on the gut microbiome for C. difficile Infection (CDI) treatment. The data showed increased beneficial bacteria, reversing dysbiosis and contributing to CDI anti-recurrence. Ibezapolstat's favorable pharmacokinetics were confirmed with low systemic exposure and high colonic concentrations.
Additionally, certain ACX-375 DNA pol IIIC analogues demonstrated in vitro activity against Anthrax (B. anthracis), including ciprofloxacin-resistant strains. Acurx is planning an Anthrax bioterrorism development program.
The company is preparing to advance ibezapolstat into international Phase 3 clinical trials for CDI treatment and submit requests for regulatory guidance in various countries. Ibezapolstat has previously received FDA QIDP and Fast-Track Designation.
FAQ
What is the current stock price of Acurx Pharmaceuticals (ACXP)?
What is the market cap of Acurx Pharmaceuticals (ACXP)?
